mRNA Expression of Bax, Bcl-2, p53, Cathepsin B, Caspase-3 and Caspase-9 in the HepG2 Cell Line Following Induction by a Novel Monoclonal Ab Hep88 mAb: Cross-Talk for Paraptosis and Apoptosis.

Monoclonal antibodies with specific antigens have been widely used as targeted therapy for cancer. Hep88 mAb is a monoclonal antibody which shows specific binding with anti-cancer effects against the HepG2 cell line. However, its mechanisms of action are still not completely understood.

Hep88 mAb-mediated paraptosis-like apoptosis in HepG2 cells via downstream upregulation and activation of caspase-3, caspase-8 and caspase-9.

Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide. Presently, targeted therapy via monoclonal antibodies to specific tumor-associated antigens is being continuously developed. Hep88 mAb has proven to exert tumoricidal effects on the HepG2 cell via a paraptosis-like morphology.

Hep 88 mAB induced ultrastructural alteration through apoptosis like program cell death in hepatocellular carcinoma.

Hep88 mAbs, a novel monoclonal antibodies against hepatocellular carcinoma cell line from Thai patient, has been proved earlier for its tumoricidal effect on HepG2 cell line. In the present study, we investigated not only Hep88 mAb's targeted proteins from HepG2 cell line by western blot analysis but also its inhibitory activity on those cells by MTT assay. Moreover the ultrastructural alteration induced by Hep88 mAb of HepG2 cell line compare with Chang liver cell line was also examined.

Association between UGT 1A1 Gly71Arg (G71R) polymorphism and neonatal hyperbilirubinemia.

Background: Neonatal hyperbilirubinemia is a common problem in neonates and affects 60% of Asian newborn babies which is twice that found in Caucasians. These findings suggest that a genetic factor might be involved. Recently, a relationship between polymorphisms of the bilirubin uridine 5-diphosphate-glucuronosyltransferase (UGTA1) gene and neonatal hyperbilirubinemia has been reported.